Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Argenx Se ( (ARGX) ) has provided an announcement.
On October 3, 2025, Argenx SE announced that it will hold an Extraordinary General Meeting of Shareholders on November 18, 2025, in Amsterdam. The meeting will address the adoption of a revised remuneration policy, and shareholders are encouraged to participate via electronic proxy voting. This meeting is significant for stakeholders as it may impact the company’s governance and strategic direction.
The most recent analyst rating on (ARGX) stock is a Buy with a $1040.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.
Spark’s Take on ARGX Stock
According to Spark, TipRanks’ AI Analyst, ARGX is a Outperform.
Argenx Se’s strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. The company’s robust revenue growth and strategic pipeline advancements are significant strengths. However, technical indicators suggest the stock may be overbought, and its high valuation poses a risk. Operational efficiency and cash flow challenges remain areas for improvement.
To see Spark’s full report on ARGX stock, click here.
More about Argenx Se
Argenx SE is a global immunology company focused on developing innovative antibody-based medicines to treat severe autoimmune diseases. The company collaborates with leading academic researchers through its Immunology Innovation Program to translate immunology breakthroughs into a portfolio of novel treatments. Argenx has developed and commercialized the first approved neonatal Fc receptor (FcRn) blocker and is exploring its potential across various autoimmune conditions.
Average Trading Volume: 401,159
Technical Sentiment Signal: Buy
Current Market Cap: $48.3B
For detailed information about ARGX stock, go to TipRanks’ Stock Analysis page.